FdaApplication
NDA 203188
Identifiers
- fda_app_no: NDA203188
Properties
| Property | Value |
|---|---|
| applicant_name | VERTEX PHARMACEUTICALS INC |
| application_type | NDA |
| approval_date | 2012-01-31 |
Revenue by product
KALYDECO
| Period | Revenue |
|---|---|
| Q4 2023 | $112.4M |
| Q3 2023 | $112.8M |
| Q4 2022 | $136.1M |
| Q3 2022 | $139.4M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| KALYDECO | IVACAFTOR | 150MG | TABLET;ORAL |
1 product